top of page



Partner
AmMax Partnering
Partnering is a critical part of AmMax’s integrated growth strategy. It was initially built on the partnership with Amgen via the licensing of a potent monoclonal antibody targeting CSF1R. Following the partnership with Evopoint Biosciences, AmMax brought in a next generation ADC with the potential to address multiple solid tumors.
We are actively seeking to license in or acquire additional oncology assets. We are also looking to out-license a number of non-core assets. Please contact laurazhu@ammaxbio.com for further information.

LifeMax licensed the worldwide rights to AMG820, now designated AMB-05X, which is in clinical development for tenosynovial giant cell tumor. The same molecule is also being developed for idiopathic pulmonary fibrosis, polycystic kidney diseases and an undisclosed indication.

AmMax entered into an exclusive option to license agreement with Evopoint for the ex-China right to develop and commercialize a next generation ADC, now designated AMB-101, for the potential treatment of a broad range of solid tumors.
bottom of page